Item
(µM/ml) |
Control
n=20 |
Methotrexate
n=63 |
Leflunomide
n=31 |
NO2-ser |
1,30 ± 0,11 |
BT 2,44 ± 0,68
AT 3,33 ± 0,59 |
BT 1,38 ± 0,31
AT 0,25 ± 0,13* ◊ |
NO3-ser |
1,17 ± 0,08 |
BT 1,13 ± 0,28
AT 2,01 ± 0,58 |
BT 0,61 ± 0,27
AT 0,42 ± 0,11* |
NO-ser |
2,47 ± 0,10 |
BT 3,49 ± 0,54
AT 5,35 ± 0,95 |
BT 2,03 ± 0,18
AT 0,67 ± 0,12* ◊ |
NO2-m |
1,12 ± 0,31 |
BT 9,31 ± 1,66*
AT 14,21 ± 1,07* |
BT 10,06 ± 2,79*
AT 9,54 ± 1,32* |
NO3-m |
0,58 ± 0,09 |
BT 15,55 ± 3,75*
AT 20,34 ± 2,23* |
BT 12,35 ± 8,15*
AT 10,54 ± 3,54* |
NO-m |
1,71 ± 0,12 |
BT 24,86 ± 4,01*
AT 34,45 ± 1,75* |
BT 22,42 ± 6,18*
AT 20,08 ± 2,76* |
NO2-sin |
1,08 ± 0,07 |
BT 7,94 ± 1,46*
AT 2,56 ± 0,54 ◊ |
BT 6,34 ± 1,22*
AT 2,32 ± 1,43 ◊ |
NO3-sin |
0,58 ± 0,04 |
BT 12,22 ± 6,21*
AT 0,23 ± 0,02 |
BT 14,32 ± 3,34*
AT 5,77 ± 1,22* |
NO-sin |
1,66 ± 0,11 |
BT 0,16 ± 4,47*
AT 2,79 ± 1,23 ◊ |
BT 20,66 ± 4,87*
AT 8,09 ± 1,55* |
Note: n — number of patients in each group. * — differences from the control were significant at р<0.05. ◊ — differences between the groups were significant at р<0.05.
BT – before treatment. AT – after treatment |